Announcements Trials
Browse Landscape

Phase

Phase 2 268Phase 1 193Phase 1/2 79Phase NA 72Phase 3 56Phase EARLY_PHASE1 17Phase 4 15Phase 2/3 4

Status

Completed 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Breast Neoplasms 40Neoplasms 36Prostatic Neoplasms 32Colorectal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasm Metastasis 14Polycystic Ovary Syndrome 13Lung Neoplasms 13Stomach Neoplasms 12Multiple Myeloma 11Carcinoma, Hepatocellular 11Recurrence 10Pancreatic Neoplasms 10Urinary Bladder Neoplasms 9Lymphoma 9Leukemia 9Myelodysplastic Syndromes 8Motor Activity 8Head and Neck Neoplasms 8Liver Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Esophageal Neoplasms 7Colonic Neoplasms 7Brain Neoplasms 7Pain 6Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6

Interventions

peginterferon alfa-2a 1naptumomab estafenatox 1Interferon-alpha 1Interferon alpha-2 1G250 monoclonal antibody 1Anesthesia, Epidural 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Carcinoma, Renal Cell × Clear all
NCT02883153 2017-06-19

Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

Radboud University Medical Center

Phase 2/3 Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Hoffmann-La Roche

Phase 2/3 Completed
9 enrolled 7 charts
DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00420888 2015-07-22

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Active Biotech AB

Phase 2/3 Completed
526 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02030717 2015-06-04

ASA

Umeå University

Phase 2/3 Completed
120 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡